{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:18:48Z","timestamp":1793305128824,"version":"4.5.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["267806"],"award-info":[{"award-number":["267806"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008644","name":"Faculty of Medicine, McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008644","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jhepr.2020.100067","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:55:09Z","timestamp":1579521309000},"page":"100067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":257,"title":["Limitations of non-invasive tests for assessment of liver fibrosis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-3127","authenticated-orcid":false,"given":"Keyur","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-8283","authenticated-orcid":false,"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2020.100067_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/path.1397","article-title":"Liver extracellular matrix in health and disease","volume":"200","author":"Bedossa","year":"2003","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jhepr.2020.100067_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jhep.2008.07.039","article-title":"Exceeding the limits of liver histology markers","volume":"50","author":"Mehta","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2007.03252.x","article-title":"Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation","volume":"25","author":"Poynard","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2020.100067_bib8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2020.100067_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1309\/W3XCNT4HKFBN2G0B","article-title":"A\u00a0systematic review of the quality of liver biopsy specimens","volume":"125","author":"Cholongitas","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jhepr.2020.100067_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gut.2005.084475","article-title":"An appraisal of the histopathological assessment of liver fibrosis","volume":"55","author":"Standish","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100067_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1542-3565(05)00541-0","article-title":"Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C","volume":"3","author":"Schiano","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8278(03)00191-0","article-title":"Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease","volume":"39","author":"Colloredo","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1478-3231.1999.tb00033.x","article-title":"Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection","volume":"19","author":"Westin","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.jhepr.2020.100067_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.20535","article-title":"Sources of variability in histological scoring of chronic viral hepatitis","volume":"41","author":"Rousselet","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib19","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib20","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2020.100067_bib21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.21595","article-title":"Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis","volume":"45","author":"Goodman","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib22","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/hep.23211","article-title":"Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial","volume":"50","author":"Goodman","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1053\/j.gastro.2009.12.003","article-title":"Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection","volume":"138","author":"McHutchison","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib24","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jhep.2013.12.023","article-title":"Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis","volume":"60","author":"Tsochatzis","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/modpathol.2013.225","article-title":"Quantification of portal-bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C","volume":"27","author":"Sandrini","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2020.100067_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2014.02.015","article-title":"qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients","volume":"61","author":"Xu","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2009.12.009","article-title":"Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis","volume":"52","author":"Gailhouste","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib28","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","article-title":"Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations","volume":"51","author":"Castera","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1440-1746.2010.06510.x","article-title":"Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population","volume":"26","author":"Wong","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib32","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hep.24694","article-title":"\u201cNormal\u201d liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country","volume":"55","author":"Das","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/hep.24624","article-title":"Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients","volume":"55","author":"Myers","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib35","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL\u00a0probes in non-alcoholic fatty liver disease","volume":"68","author":"Wong","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100067_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hep.29893","article-title":"Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis","volume":"68","author":"Huang","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhepr.2020.100067_bib38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cgh.2012.01.015","article-title":"Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection","volume":"10","author":"Tapper","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.26343","article-title":"Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution","volume":"58","author":"Arena","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1053\/j.gastro.2017.03.016","article-title":"American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases","volume":"152","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1148\/radiol.2018170601","article-title":"Quantitative elastography methods in liver disease: current evidence and future directions","volume":"286","author":"Kennedy","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2020.100067_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2214\/AJR.15.14552","article-title":"Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques","volume":"205","author":"Tang","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhepr.2020.100067_bib44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00261-014-0282-y","article-title":"Cross-vendor validation of liver magnetic resonance elastography","volume":"40","author":"Serai","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.jhepr.2020.100067_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1148\/radiol.2016160863","article-title":"Technical failure of MR elastography examinations of the liver: experience from a large single-center study","volume":"284","author":"Wagner","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2020.100067_bib46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","article-title":"Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2020.100067_bib48","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A\u00a0simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib49","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jhep.2004.08.008","article-title":"Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients","volume":"41","author":"Patel","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib50","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1373\/clinchem.2005.048389","article-title":"Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection","volume":"51","author":"Adams","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhepr.2020.100067_bib51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/jhep.2002.36128","article-title":"Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model","volume":"36","author":"Forns","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep.20935","article-title":"A\u00a0novel panel of blood markers to assess the degree of liver fibrosis","volume":"42","author":"Cales","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib53","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2014.10.042","article-title":"An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards","volume":"62","author":"Boursier","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib55","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.24515","article-title":"Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?","volume":"54","author":"Guha","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/00365519209115504","article-title":"Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age","volume":"52","author":"Lindqvist","year":"1992","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jhepr.2020.100067_bib57","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2796.2005.01564.x","article-title":"Mechanisms by which food intake elevates circulating levels of hyaluronan in humans","volume":"258","author":"Fraser","year":"2005","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jhepr.2020.100067_bib58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2005.10.019","article-title":"Performance of serum marker panels for liver fibrosis in chronic hepatitis C","volume":"44","author":"Parkes","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib59","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1478-3231.2008.01789.x","article-title":"Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C","volume":"28","author":"Cales","year":"2008","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.jhepr.2020.100067_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.04.037","article-title":"Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C","volume":"12","author":"Patel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib61","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-159-5-201309030-00021","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection","volume":"159","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2020.100067_bib62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib63","doi-asserted-by":"crossref","first-page":"ofy076","DOI":"10.1093\/ofid\/ofy076","article-title":"Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a National Specialty Pharmacy Cohort Study","volume":"5","author":"Gowda","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhepr.2020.100067_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2014.03.012","article-title":"Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?","volume":"107","author":"Lee","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhepr.2020.100067_bib65","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib66","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A\u00a0morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cgh.2008.10.034","article-title":"Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis","volume":"7","author":"Fontana","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2893.2008.01055.x","article-title":"Changes of non-invasive markers and FibroScan values during HCV treatment","volume":"16","author":"Vergniol","year":"2009","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2020.100067_bib69","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3748\/wjg.v17.i41.4581","article-title":"FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus","volume":"17","author":"Patel","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2893.2008.01062.x","article-title":"An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C","volume":"16","author":"Patel","year":"2009","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2020.100067_bib71","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP1570","article-title":"Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies","volume":"15","author":"Poynard","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2020.100067_bib72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2018.11.016","article-title":"Chronic hepatitis C infection - noninvasive assessment of liver fibrosis in the era of direct acting antivirals","volume":"51","author":"Trivedi","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2020.100067_bib73","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/apt.12762","article-title":"Letter: accuracy of liver stiffness measurement - a comparison of two different FibroScan devices","volume":"39","author":"Parra-Ruiz","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2020.100067_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","article-title":"The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin","volume":"83","author":"Ogawa","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhepr.2020.100067_bib75","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","article-title":"Liver stiffness diminishes with antiviral response in chronic hepatitis C","volume":"34","author":"Hezode","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2020.100067_bib76","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.dld.2013.03.023","article-title":"Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C","volume":"45","author":"Stasi","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2020.100067_bib77","first-page":"587","article-title":"Noninvasive assessment of fibrosis regression in hepatitis C virus sustained virologic responders","volume":"13","author":"Trivedi","year":"2017","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jhepr.2020.100067_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"D'Ambrosio","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2020.100067_bib81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/liv.12393","article-title":"Hepatitis B: are non-invasive markers of liver fibrosis reliable?","volume":"34","author":"Castera","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2020.100067_bib82","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ajg.2014.21","article-title":"FibroTest\/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis","volume":"109","author":"Salkic","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib83","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"9865","key":"10.1016\/j.jhepr.2020.100067_bib84","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2020.100067_bib85","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib86","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2015.11.012","article-title":"Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients","volume":"64","author":"Kim","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib87","doi-asserted-by":"crossref","first-page":"14568","DOI":"10.3748\/wjg.v20.i40.14568","article-title":"Non-invasive assessment of liver fibrosis in chronic hepatitis B","volume":"20","author":"Branchi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib88","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jhep.2010.07.033","article-title":"Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy","volume":"54","author":"Tsochatzis","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib89","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1478-3231.2011.02663.x","article-title":"Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C","volume":"32","author":"Verveer","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2020.100067_bib90","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2010.07.017","article-title":"Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C","volume":"54","author":"Fraquelli","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib91","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/00365521.2011.565068","article-title":"Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs","volume":"46","author":"Andersen","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib92","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/apt.12307","article-title":"Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus","volume":"37","author":"de Ledinghen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2020.100067_bib93","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib94","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib95","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.jhepr.2020.100067_bib96","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib97","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus","volume":"67","author":"Bril","year":"2019","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.jhepr.2020.100067_bib99","doi-asserted-by":"crossref","first-page":"e0160526","DOI":"10.1371\/journal.pone.0160526","article-title":"Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease","volume":"11","author":"Xia","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2020.100067_bib100","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib101","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/jgh.12614","article-title":"Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis","volume":"29","author":"Miller","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib102","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.28002","article-title":"A\u00a0novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers","volume":"62","author":"Kamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib103","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1194\/jlr.P055640","article-title":"Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis","volume":"56","author":"Loomba","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2020.100067_bib104","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib105","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.jhepr.2020.100067_bib106","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib107","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with non-alcoholic fatty liver disease","author":"Grimaudo","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib108","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","article-title":"Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease","volume":"66","author":"Hardy","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100067_bib109","doi-asserted-by":"crossref","first-page":"43238","DOI":"10.1038\/srep43238","article-title":"A\u00a0multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains","volume":"7","author":"Wood","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2020.100067_bib110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrgastro.2013.87","article-title":"MicroRNAs in liver disease","volume":"10","author":"Szabo","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib111","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.gastro.2016.09.065","article-title":"Using big data to discover diagnostics and therapeutics for gastrointestinal and liver diseases","volume":"152","author":"Wooden","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib112","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1053\/j.gastro.2016.03.008","article-title":"Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease","volume":"150","author":"Bedossa","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib113","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib115","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib116","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib117","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jhepr.2020.100067_bib118","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib119","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MOG.0000000000000167","article-title":"Noninvasive assessment of liver function","volume":"31","author":"Helmke","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib120","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib121","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, Quantitative Assessment of liver fat by MRI-PDFF as an endpoint in NASH Trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib122","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2036.2012.05121.x","article-title":"Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD","volume":"36","author":"Permutt","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2020.100067_bib123","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.28843","article-title":"Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values","volume":"65","author":"Petta","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib124","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib125","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhepr.2020.100067_bib126","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/1756283X16656735","article-title":"Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis","volume":"9","author":"Patel","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100067_bib129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib131","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2018.11.025","article-title":"Non-invasive diagnosis and biomarkers in alcohol-related liver disease","volume":"70","author":"Moreno","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib132","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S2468-1253(18)30124-9","article-title":"Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis","volume":"3","author":"Nguyen-Khac","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib133","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1530-0277.2010.01374.x","article-title":"Effect of detoxification on liver stiffness assessed by Fibroscan(R) in alcoholic patients","volume":"35","author":"Gelsi","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhepr.2020.100067_bib134","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/hep.29099","article-title":"Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease","volume":"66","author":"Mueller","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2015.09.040","article-title":"Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis","volume":"150","author":"Thiele","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100067_bib136","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cld.2015.08.013","article-title":"Utility of noninvasive markers of fibrosis in cholestatic liver diseases","volume":"20","author":"Corpechot","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2020.100067_bib137","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/hep.22577","article-title":"Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis","volume":"48","author":"Millonig","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib138","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12072-018-9907-5","article-title":"Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2020.100067_bib139","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.12659\/MSM.907300","article-title":"Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients","volume":"23","author":"Guo","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jhepr.2020.100067_bib140","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jhep.2017.11.020","article-title":"Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis","volume":"68","author":"Hartl","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib141","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.24654","article-title":"Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive","volume":"55","author":"Boursier","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib142","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/hep.22859","article-title":"SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C","volume":"49","author":"Sebastiani","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100067_bib143","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100067_bib144","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep4.1411","article-title":"Impact of Implementing a \u201cFIB-4 First\u201d strategy on a pathway for patients with NAFLD referred from primary care","volume":"3","author":"Davyduke","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2020.100067_bib145","doi-asserted-by":"crossref","first-page":"e0208798","DOI":"10.1371\/journal.pone.0208798","article-title":"Local care and treatment of liver disease (LOCATE) - a cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care","volume":"13","author":"El-Gohary","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2020.100067_bib146","doi-asserted-by":"crossref","first-page":"e007516","DOI":"10.1136\/bmjopen-2014-007516","article-title":"Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography","volume":"5","author":"Harman","year":"2015","journal-title":"BMJ Open"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592030001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592030001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:24:12Z","timestamp":1762899852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592030001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S258955592030001X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2020.100067","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limitations of non-invasive tests for assessment of liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2020.100067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100067"}}